Beijing Kanghong Biological Medicine Co., Ltd.

This phase 3 trial tests whether the experimental drug KHN939 can reduce eye bulging and other symptoms in people with moderate-to-severe active thyroid eye disease. About 60 participants in China will receive either KHN939 or a placebo by infusion every three weeks for 21 weeks.…

This phase 3 trial is testing whether the experimental drug KHN939 can reduce eye bulging in people with moderate-to-severe inactive thyroid eye disease. About 117 participants in China will receive either KHN939 or a placebo by infusion every three weeks for 21 weeks. The main g…